-->

Intra Cellular Therapies Stock EBITDA

ITCIDelisted Stock  USD 131.87  0.03  0.02%   
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Intra Cellular's long-term financial health and intrinsic value.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Intra Cellular Therapies Company EBITDA Analysis

Intra Cellular's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Intra Cellular EBITDA

    
  (116.72 M)  
Most of Intra Cellular's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra Cellular Therapies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Intra Cellular Therapies reported earnings before interest,tax, depreciation and amortization of (116.72 Million). This is 113.3% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The ebitda for all United States stocks is 102.99% higher than that of the company.

Intra EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra Cellular's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra Cellular could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics of similar companies.
Intra Cellular is currently under evaluation in ebitda category among its peers.

Intra Fundamentals

About Intra Cellular Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra Cellular Therapies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra Cellular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra Cellular Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Intra Stock

If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Commodity Directory
Find actively traded commodities issued by global exchanges